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Study question: Can we develop a prediction model which can estimate the chances of conception 29 
leading to live birth with and without treatment at different points in time in couples with 30 
unexplained subfertility? 31 
Summary answer: Yes a dynamic model was developed which predicted the probability of 32 
conceiving under expectant management and following active treatments (IVF, intrauterine 33 
insemination with ovarian stimulation (IUI+SO), clomiphene) at different points in time since 34 
diagnosis.  35 
What is known already: Couples with no identified cause for their subfertility continue to have a 36 
realistic chance of conceiving naturally which makes it difficult for clinicians to decide when to 37 
intervene. Previous fertility prediction models have attempted to address this by separately 38 
estimating either the chances of natural conception or the chances of conception following certain 39 
treatments.  These models only make predictions at a single point in time and are therefore 40 
inadequate for informing continued decision making at subsequent consultations.  41 
Study design, size, duration: A population-based study of 1,316 couples with unexplained 42 
subfertility attending a regional clinic between 1998 and 2011. 43 
Participants, setting, methods: A dynamic prediction model was developed which estimates the 44 
chances of conception within six months from the point when a diagnosis of unexplained subfertility 45 
was made.  These predictions were recomputed each month to provide a dynamic assessment of the 46 
individualised chances of conception whilst taking account of treatment status in each month. 47 
Conception must have led to live birth and treatments included clomiphene, IUI+SO, and IVF. 48 
Predictions for natural conception were externally validated using a prospective cohort from The 49 
Netherlands.  50 
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Main results and the role of chance: 554 (42%) couples started fertility treatment within two years 51 
of their first fertility consultation. The natural conception leading to live birth rate was 0.24 natural 52 
conceptions per couple per year. Active treatment had a higher chance of conception compared to 53 
those who remained under expectant management. This association ranged from weak with 54 
clomiphene to strong with IVF [clomiphene, Hazard Ratio (HR)=1.42 (95% CI 1.05 to 1.91); IUI+SO, 55 
HR=2.90 (2.06 to 4.08); IVF, HR=5.09 (4.04 to 6.40)]. Female age and duration of subfertility were 56 
significant predictors, without clear interaction with the relative effect of treatment.   57 
Limitations, reasons for caution: We were unable to adjust for other potentially important 58 
predictors, e.g. measures of ovarian reserve, which were not available in the linked Grampian 59 
dataset which may have made predictions more specific. This study was conducted using single 60 
centre data meaning that it may not be generalizable to other centres.  However, the model 61 
performed as well as previous models in reproductive medicine when externally validated using the 62 
Dutch cohort.  63 
Wider implications of the findings:  For the first time, it is possible to estimate the chances of 64 
conception following expectant management and different fertility treatments over time in couples 65 
with unexplained subfertility. This information will help inform couples and their clinicians of their 66 
likely chances of success which may help manage expectations, not only at diagnostic workup 67 
completion but throughout their fertility journey. 68 
Study funding/competing interest(s): This work was supported by a Chief Scientist Office 69 
postdoctoral training fellowship in health services research and health of the public research (ref 70 
PDF/12/06). BWM is supported by a NHMRC Practitioner Fellowship (GNT1082548). BWM reports 71 
consultancy for ObsEva, Merck and Guerbet. None of the other authors declare any conflicts of 72 
interest. 73 










Infertility or subfertility, defined as the failure to achieve a clinical pregnancy after at least 12 80 
months of regular unprotected sexual intercourse (Zegers-Hochschild et al., 2009), affects around 81 
one in six couples (Oakley et al., 2008; Mascarenhas et al., 2012; Zhou et al., 2017).  In approximately 82 
a third of them the cause of subfertility remains unexplained after routine investigations. Although 83 
many will conceive naturally, couples are often unaware of this and equate their condition to 84 
sterility (te Velde and Cohlen, 1999; Gnoth et al., 2003; Hunault et al., 2004; van der Steeg et al., 85 
2007).  This has encouraged many to seek early access to assisted reproductive technology 86 
(Kamphuis et al., 2014), resulting in a steady increase in the number of IVF cycles each year 87 
(Ferraretti et al., 2017; Fitzgerald et al., 2017).  For example, in the UK, the proportion of all IVF 88 
cycles undertaken for unexplained subfertility has increased from 17.5% in 2000 to 27.6% in 2014 89 
(HFEA, 2008; HFEA, 2016). 90 
A few clinical trials of moderate quality have questioned the strategy of active treatment using 91 
either clomiphene citrate, intrauterine insemination with ovarian stimulation (IUI+SO) or IVF in 92 
couples with unexplained subfertility with reasonably high rates of spontaneous conception 93 
(Bhattacharya et al., 2008; Pandian et al., 2015; Brandes et al., 2011; Tjon-Kon-Fat et al., 2016; 94 
Bahadur et al., 2016).  However, such couples do not have the same chances of conceiving and a 95 
previous prediction model has been used in The Netherlands to identify those with an initial poor 96 
prognosis (Hunault et al., 2004).  Other prediction models developed so far have attempted to 97 
estimate the probability of live birth following certain treatments at a single point in time, but their 98 
clinical utility has been limited by their inability to update the chances of conception in the same 99 
couples at different time points (Leushuis et al., 2009).  As couples with better prognoses become 100 
pregnant, those remaining behind represent an increasingly biased group with poorer prognoses. 101 
Reapplication of a model, developed at an earlier point when couples have better prognosis, to this 102 
group of patients has a tendency to overestimate predicted success (van Eekelen et al., 2017).  So 103 
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far, only one study has made repeated predictions over time of the chances of natural conception 104 
(van Eekelen et al., 2017).     105 
Another reason why the ability to assess the prognosis of a couple with unexplained subfertility at 106 
different points in time is critical is because it influences decisions around whether, and when, active 107 
treatment should be offered (McLernon et al., 2014; ESHRE Capri Workshop Group, 2017).  Previous 108 
models were unable to assess both the individualised chances of natural conception and conception 109 
related to different fertility treatments together - mainly due to the lack of suitable integrated follow 110 
up data.  By estimating how a couple’s chance of conception evolves over time, both naturally and 111 
following different fertility treatments, clinicians will have a better understanding of how to manage 112 
such patients. 113 
Our aim was to develop and validate a prediction model which can generate dynamic estimates of 114 
the chances of conception leading to live birth in couples with unexplained subfertility using a 115 
unique record-linked observational database of fertility diagnosis, fertility treatment and pregnancy 116 
outcome records (Pandey et al., 2014).  We intended that the model should also take into account 117 
any potential impact of active treatment by clomiphene, IUI+SO and IVF.  118 
 119 
Methods 120 
Study population 121 
This observational study included all couples residing in the Grampian region of Scotland who 122 
registered with the Aberdeen Fertility Centre from 1998 to 2011 with unexplained subfertility, i.e. no 123 
medically known cause for their barrier to conception following normal tests for tubal patency, 124 
semen analysis and ovulation (see supplementary text file 1; fig. S1).  We excluded women aged 125 
younger than 18 or older than 50 and women who had fertility treatment involving donor eggs or 126 
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sperm (fig. S2). We also excluded women who did not give consent for their IVF data to be used for 127 
research purposes. 128 
Databases 129 
The following electronic databases were obtained and record-linked: 130 
Aberdeen Fertility Centre Database (AFCD): The AFCD holds all fertility diagnostic and treatment 131 
records electronically on all subfertile couples living in the Grampian region of Scotland (Pandey et 132 
al., 2014; Sripada et al., 2010; Thomson et al., 2005).  Assessments and tests were performed based 133 
on the 2004 National Institute for Health and Care Excellence (NICE) guidelines of management of 134 
infertility in the UK which have since been updated and, prior to this, Royal College Guidelines 135 
(National Collaborating Centre for Women’s and Children’s Health, 2013).  Details of the clinical 136 
protocols used in decision-making at Aberdeen Fertility Clinic are included in the Supplementary 137 
material (supplementary text file 1). Data entry in the AFCD is validated and checked by regular case 138 
note audits.  139 
Assisted Reproduction Unit Database (ARUD): The ARUD contains information on all IVF including 140 
intracytoplasmic sperm injection (ICSI) treatment cycles since 1998. The ARUD was record-linked to 141 
the AFCD to identify couples who had fertility treatment.  ARUD statistics are validated against 142 
annual HFEA reports on treatment cycles and outcomes.  Access to the AFCD and ARUD was 143 
approved by the Aberdeen Fertility Databases Steering Committee. 144 
Aberdeen Maternity and Neonatal Databank (AMND): Live births were identified through record-145 
linkage with the AMND, which has held obstetric records on all women residing in Aberdeen City 146 
District since 1950 (Pandey et al., 2014; Maheshwari et al., 2009; Maheshwari et al., 2010).  147 
Completeness of the AMND is checked annually against the number of deliveries recorded in the 148 
NHS records office. There are several validity checks incorporated within the database to ensure 149 
against invalid data entry.  Access to the AMND was granted by the AMND Steering Committee. 150 
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Scottish Morbidity Records SMR02 Maternity & Neonatal Linked Dataset (SMR02): A proportion of 151 
women residing in the Grampian region but outside the catchment area of Aberdeen Maternity 152 
Hospital will have delivered in other maternity hospitals. Therefore the SMR02 dataset was obtained 153 
which includes maternity inpatients and day-cases receiving care in the obstetrics specialty for the 154 
whole of Scotland. Records were extracted from these datasets for the period between 1992 and 155 
2012. Access to the SMR02 linked dataset was approved by the Privacy Advisory Committee of 156 
Information Services Division Scotland. 157 
In Scotland, all individuals registered with a general practitioner have a unique identifier, the 158 
Community Health Index (CHI) (Evans and MacDonald, 1999).  The Data Management Team, 159 
University of Aberdeen, securely hold the CHI files for NHS Grampian.  The CHI files contain the CHI 160 
number and the patient’s name, address and date of birth and enable record-linkage of healthcare 161 
datasets. All identifiers within the above datasets were removed and replaced with a study specific 162 
unique identifier.  The pseudonymised datasets were stored within the Grampian Data Safe Haven 163 
(DaSH).  This process was carried out according to the Standard Operating Procedures of the Data 164 
Management Team, University of Aberdeen.  The first author (DJM) then record-linked the 165 
databases using the unique identifier.  166 
Baseline characteristics 167 
Baseline couple characteristics were extracted from the AFCD and included female age, duration of 168 
subfertility, female smoking status (current versus never/ex), female alcohol status (current versus 169 
never/ex) and previous pregnancy status at registration. Furthermore, the AFCD provided details 170 
(including dates) of treatment with clomiphene citrate and IUI+SO (where the ovarian stimulation is 171 
injections (gonadotrophins) alone or a combination of tablets (clomiphene) and injections depending 172 
on the individual case) treatments that occurred during follow-up.  Details of IVF treatment were 173 




The primary outcome at any point in time, was the occurrence of conception within six months 176 
leading to a live birth (shortened to conception for the remainder of this article).  The predicted 177 
chance of this outcome was first calculated at the point of completion of diagnostic workup (defined 178 
as approximately three months after first fertility clinic appointment) and again at every subsequent 179 
month until two years after the first appointment (as described below). 180 
Statistical analysis 181 
Descriptive statistics were used to characterise couples at their first fertility clinic appointment. The 182 
number (%) of women treated by treatment type up to a maximum of two years and the median 183 
time to first treatment were calculated. The frequency of each pattern of sequential treatments was 184 
tabulated. The number (%) of conceptions leading to live birth was calculated and grouped into 185 
treatment dependent and treatment independent outcomes. The latter group was further split into 186 
those occurring without any previous treatment and those following unsuccessful treatment. 187 
Conception leading to live birth was classified as treatment dependent if this outcome was recorded 188 
in the treatment records or if the ‘date of conception’ (found by subtracting the gestational age of 189 
the baby from the date of delivery) occurred any time during the four weeks prior to date of 190 
treatment. 191 
Dynamic prediction 192 
Dynamic prediction modelling using a landmarking approach was conducted to estimate the chances 193 
of conception within six months from completion of diagnostic workup (van Houwelingen and 194 
Putter, 2012).  These chances were updated from every subsequent month until two years after the 195 
first fertility clinic appointment (22 times in total). In the dynamic process, the crudest model would 196 
involve fitting 22 Cox regression models, each with a separate time origin for each consecutive 197 
month with a follow-up window of six months in each. In each model the treatment status would be 198 
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updated for that particular month of prediction. As this window slides forward with each successive 199 
month any women who conceived in the previous month were excluded from future models. Figure 200 
S3 explains the dynamic prediction process for a hypothetical case. Rather than fit 22 separate 201 
models which may lead to unstable predictions, we modelled the dynamic process in one 202 
‘supermodel’ by adding month of prediction as a predictor (linear and quadratic effect) (van 203 
Houwelingen and Putter, 2012).  Treatment status was the only predictor that was allowed to vary at 204 
the month of prediction and was initially coded as: expectant management (never had any 205 
treatment - reference category), clomiphene, IUI+SO as the first treatment, IVF as the first 206 
treatment, IUI+SO having had previous IUI+SO or IVF since diagnostic workup, IVF having had 207 
previous IUI+SO or IVF since diagnostic workup, and, no treatment having had previous treatment 208 
since diagnostic workup (which we call ‘break from treatment’). However, we found that initial IVF 209 
treatment versus continued IVF treatment and initial IUI+SO versus continued IUI+SO had very 210 
similar effects and were therefore combined.  ‘Break from treatment’ represents those months in 211 
between treatment cycles when the couples under the treatment pathway do not have any 212 
treatment. It is essentially a ‘nuisance’ category that must be included in the model since it is the 213 
only monthly treatment status remaining after we consider months of expectant management and 214 
fertility treatment. It should be noted, however, that from such a month we can still make a 215 
prediction over the following six months during which time they can undergo further treatment as 216 
observed in the data. The known predictors of conception female age, previous pregnancy, and 217 
duration of subfertility were included in the model at their values at registration.  Female age was 218 
found to have a non-linear relationship with the log hazard of conception and was fitted as a two-219 
piece linear term i.e. it was modelled as separate linear effects from 18 to 31 years and from 32 to 220 
50 years. Year of registration was included as a linear predictor to account for changes in practice 221 
over the 14 year study period. Other available potential predictors, including female smoking and 222 
alcohol status and female BMI were added to the initial model but removed if they were not 223 
statistically significant.  Since female BMI was missing in 20% of women, multiple imputation was 224 
11 
 
performed to impute these values. BMI was not statistically significant (p=0.99) and was removed 225 
from the model. Further details are in the supplementary text file 2. 226 
Predictive ability  227 
We assessed the apparent discriminatory ability of the dynamic prediction model by calculating the 228 
concordance statistic for survival time data at each prediction month (Kremers, 2007).  Dynamic 229 
calibration plots were used to determine whether the predicted probabilities agreed with the 230 
observed rates of conception.  231 
External validation 232 
Data from a prospective cohort of patients recruited from 38 hospitals in the Netherlands was used 233 
to externally validate predictions for couples under expectant management. The validation cohort 234 
contained 5184 patients who were referred for an infertility work up between 2002 and 2004 (van 235 
der Steeg et al., 2007; van Eekelen et al., 2017).  We selected couples without any major barriers to 236 
conception i.e. those with regular menstrual cycles (cycle length between 23 and 35 days), at least 237 
one patent fallopian tube and semen analyses with a total motile sperm count >1 × 106. Unlike the 238 
Grampian record-linked data which followed up women until conception leading to live birth, the 239 
Dutch cohort followed couples until natural conception leading to an ongoing pregnancy, defined as 240 
the presence of foetal cardiac activity at transvaginal sonography at a gestational age of at least 12 241 
weeks.  Therefore, this outcome was used instead of live birth in the validation.  If no pregnancy 242 
occurred, then follow-up time was censored at the start of treatment or at the last date of contact 243 
during follow-up.  This meant that we could only validate our model with a cohort following couples 244 
for natural conception.  The van Eekelen study accounted for missing data by multiple imputation 245 
and we used one randomly chosen imputed dataset for validation (van Eekelen et al., 2017). 246 
The parameter estimates of the final model from the Grampian cohort were applied to the 247 
validation cohort to assess its predictive ability. Again, the concordance statistic was used as the 248 
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measure of discrimination. Calibration-in-the-large (whether the outcome is systematically over or 249 
under estimated) was assessed visually by plotting the observed chance of conception within six 250 
months (with 95% CI, using Kaplan-Meier estimate) against the average predicted probability of 251 
conception within six months for every month since diagnosis. A calibration slope test was 252 
conducted to test for overfitting of the model by applying the final model to the Dutch dataset to 253 
calculate the linear predictor value for each woman.  This linear predictor was then fitted in a new 254 
model on its own and its slope estimated. A value significantly below one signifies overfitting. 255 
Secondary analysis 256 
Although the above model provides individualised absolute predictions of conception at every 257 
month since diagnosis, the relative treatment estimates are assumed to be the same at each month.  258 
We explored whether the treatment estimates vary for couples with different prognosis by fitting 259 
interactions between treatment status and each baseline predictor. However, due to the modest 260 
sample size this approach leads to overfitting when included with all predictors. An alternative 261 
method is to estimate a baseline prognostic score for each couple which is a variable that represents 262 
the linear combination of all the predictors in the model (also called the linear predictor or Xẞ). This 263 
is done by fitting a standard Cox regression model predicting time to conception with female age, 264 
duration of subfertility, previous pregnancy status and year of registration as predictors.  This 265 
prognostic score, summarizing all the baseline predictors, was calculated and included in a separate 266 
dynamic prediction model as a main effect and as an interaction term with treatment status.  267 
Dynamic prediction plots showing the estimated chances of conception by treatment status were 268 
presented for couples with poor, average and good prognosis (each defined as the 10th, 50th (i.e. 269 
median), and 90th percentile value of the prognostic score respectively).  The 95% pointwise 270 
confidence limits were estimated from the model and included in the plots.  271 
Statistical analysis was carried out using SAS (V.9.3) (SAS Institute, Cary, NC) and the dynpred 272 
package in R (v3.3.3) (R Foundation for Statistical Computing, Vienna, Austria) (Putter, 2015). 273 
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Ethical approval: The study was approved by the North of Scotland Research Ethics Committee 274 
(12/NS/0120). 275 
Results 276 
A total of 1507 couples were diagnosed with unexplained subfertility after attending AFC for their 277 
first consultation between 1998 and 2011 (see fig. S2).  We excluded a further 191 couples who 278 
conceived during the three month period between their first appointment and completion of 279 
workup. The descriptive characteristics of the remaining 1316 couples are shown in Table I.  The only 280 
substantial set of missing data was for female BMI (missing in 21%).   281 
Out of the 1316 couples, 554 (42%) started treatment within two years of their first appointment.  282 
The median (IQR) time to first fertility treatment was 10.9 (5.8, 16.0) months (Table S1). The first 283 
treatment was clomiphene in 263 (47%) women. Of these, 147 only had clomiphene treatment, 91 284 
went from a course of clomiphene to IVF (without IUI) and 25 went from clomiphene to IUI+SO. The 285 
first treatment was IVF in 184 (33%) women (with 16 subsequently having IUI+SO) and IUI+SO in 107 286 
(19%) women (55 only had IUI+SO and 52 went on to have IVF) (Table S1).  Over two years the most 287 
frequent treatment pathway was one fresh cycle of IVF (n=73; 13%) (see Table S2 for other 288 
treatment pathways). In the month when a patient started clomiphene treatment, the mean (SD) 289 
number of clomiphene treatments observed over the following six months was 3.6 (1.8). For IUI and 290 
IVF treatments the mean (SD) was 1.7 (0.8) and 1.4 (0.5) respectively. At one year post-workup, a 291 
couple who are under the treatment pathway but who happen to have no treatment in that month 292 
have a mean (SD) number of treatments over the following six months equal to 0.43 (0.61). In 293 
comparison, those still under expectant management at one year post-workup have a mean (SD) 294 
number of treatments over the following six months equal to 0.23 (0.66). 295 
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From the point of workup completion to 27 months later the conception leading to live birth rate 296 
was 0.24 conceptions per couple per year. From the point of treatment to 27 months after workup, 297 
the conception leading to live birth rate was 0.39 conceptions per couple per year. 298 
Dynamic prediction of conception leading to live birth 299 
Twenty four women had missing information on duration of subfertility and previous pregnancy 300 
status and were excluded from further analysis. For ease of interpretation of treatment predictor 301 
effects, Table II presents the hazard ratios with 95% CIs from the final dynamic model. The dynamic 302 
prediction model showed that female age at baseline had no significant effect on the likelihood of 303 
conception until the age of 32, at which point, the chances decreased by 11% for each yearly 304 
increase in age (Hazard Ratio (95% CI) = 0.89 (0.86 to 0.92)). Increasing duration of subfertility was 305 
also associated with a decreased chance of conception. The chances of conception in women with 306 
no previous pregnancy were 14% lower than in women who had been pregnant before, but this was 307 
not statistically significant. The effects of female smoking and female alcohol consumption were 308 
weak and hence not included in the final model.  309 
On average, couples who had IUI+SO were almost three times as likely to conceive within six months 310 
as couples who were under expectant management (HR=2.90 (2.06 to 4.08)).  For couples who had 311 
IVF treatment the chances of conception leading to live birth were five times higher compared with 312 
expectant management (HR=5.09 (4.04 to 6.40)). The chances of conception following clomiphene 313 
(versus expectant management) were only slightly higher (HR=1.42 (1.05 to 1.91)). In the months 314 
between treatments, when a couple do not have any treatment, their chances of conception over 315 
the following six months were 50% higher compared to couples under expectant management.  316 
Internal validation 317 
The concordance (95% CI) for the dynamic prediction model was 0.60 (0.57 to 0.64) for predictions 318 
from workup completion increasing to 0.71 (0.65 to 0.77) for predictions from 21 months post 319 
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workup (Table S3). For all treatment groups, the dynamic predictions lay within the 95% CIs of the 320 
observed dynamic probabilities (in months where there were enough treated couples to make a 321 
Kaplan-Meier estimate).   322 
External validation 323 
The descriptive characteristics of predictors included in the dynamic model were reasonably similar 324 
between the Grampian and Dutch cohorts (Table I). From the point of workup completion to 27 325 
months later the ongoing pregnancy rate following natural conception was 0.32 per couple per year. 326 
The discriminatory ability of the model applied to the Dutch cohort showed a concordance statistic 327 
of 0.63 (0.60 to 0.65) for predictions made at diagnostic workup completion. These ranged from 0.56 328 
to 0.68 over the prediction months (Fig 1A and Table S3).  The dynamic calibration plot (see Fig 1B) 329 
showed minor evidence of overestimation for predictions at month of workup and at 2 and 16 330 
months post workup. The ratio of observed chance of conception within six months to predicted 331 
probability of conception within six months varied from 0.65 at month 16 to 1.06 at month 6. From 332 
month three to ten the ratio ranged from 0.95 to 1.06. The calibration slope showed only minor 333 
evidence of overfitting (slope=0.968 (95% CI 0.935 to 1.002); p-value for deviation from unity = 334 
0.06). 335 
Predictions for two hypothetical couples 336 
Figure 2 displays the dynamic predictions for two different hypothetical couples. Couple A have been 337 
trying to conceive for one year, have never been previously pregnant and the female partner is 30 338 
years old. At each month following diagnostic workup, the blue line represents the probability of 339 
conceiving over the following six months for women who were managed expectantly in that month. 340 
At the point of workup completion (month 0 in Figure 2) Couple A’s chance of conception over the 341 
following six months is 31% (95% CI 25% to 37%). The other solid lines on the plot represent the 342 
probability of conception over six months when shifting from expectant management to fertility 343 
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treatment in a given month. All treatments resulted in an increased chance of conception over the 344 
following six months. For example, six months after diagnosis, if they are still under expectant 345 
management, Couple A’s chances of conception over the following six months reduce to 20% (95% 346 
CI 15% to 24%). Their probability would increase slightly to 27% (95% CI 18% to 35%) if the female 347 
partner starts clomiphene at month six (result not shown). However, if she starts IUI+SO at month 348 
six her chance is 47% (95% CI 31% to 59%) (green line on Fig 2) whereas if she starts IVF at month six 349 
her chance of conception within the next six months is 67% (53% to 77%) (red line on Fig 2). Twelve 350 
months after diagnostic workup, their chance of conception over the next six months decrease to 351 
17% (13% to 22%) if the couple continues to try naturally. If the couple start treatment with 352 
clomiphene, IUI+SO or IVF 12 months after diagnosis their chances of conceiving would be 24% (15% 353 
to 31%), 42% (27% to 54%) and 62% (47% to 72%) respectively.  See supplementary text file 3 for a 354 
demonstration on how to calculate these predictions using the model formula. 355 
 356 
Secondary analysis 357 
The chances of conception by treatment status did not vary for couples with different baseline 358 
characteristics (i.e. the interactive effect was not statistically significant, p=0.26). Dynamic prediction 359 
plots showing the estimated chances of conception by treatment status are presented in Figure 3 for 360 
couples with poor, average and good prognosis.  IVF (versus expectant management) was shown to 361 
have a relatively constant hazard ratio of around five for all three prognostic levels. However, the 362 
effect of IUI+SO is stronger for poor prognosis couples and weaker for good prognosis couples. 363 
 364 
Discussion  365 
Main findings 366 
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This study provides individualised dynamic predictions of the chances of natural and treatment 367 
dependent conception leading to live birth for couples with unexplained subfertility. These 368 
predictions are estimated from the point of fertility workup completion and are updated monthly 369 
thereafter. At each month we were able to predict the impact of having different treatment 370 
(clomiphene, IUI+SO and IVF). We found that increasing age of the woman (from 32 years), 371 
increasing duration of subfertility and previous pregnancy measured at baseline were predictive of 372 
conception leading to live birth.  Treatment with either IUI+SO or IVF was associated with a higher 373 
chance of conception leading to live birth in comparison with expectant management.  374 
Strengths  375 
This project is unique in that the study cohort came from a single NHS fertility clinic with complete 376 
population coverage in the Grampian region of North East Scotland. The clinic has an NHS maternity 377 
unit with no provision of either service in the private sector. We successfully record-linked electronic 378 
patient registration, diagnostic and treatment data from Aberdeen Fertility Clinic with pregnancy 379 
outcome information from maternity hospital admissions in one defined geographical region 380 
(Hansen et al., 2015).  This provided a unique resource to follow-up couples from registration at the 381 
fertility clinic to delivery of a baby (Pandey et al., 2014),  and, for the first time, allows us to estimate 382 
the chances of conception following different fertility treatments at different time points based on a 383 
couple’s individual characteristics. 384 
With the exception of a recently published model predicting natural conception only (van Eekelen et 385 
al., 2017), previous models have only been able to predict fertility outcomes at a single point in time. 386 
While this provides an initial prognosis, it is insufficient for making clinically meaningful decisions 387 
about when to initiate fertility treatment in couples who possess a good chance of natural 388 
conception. It is far more useful to assess how the prognoses of these couples change over time in 389 
order to balance the risks and benefits of a variety of active treatments versus the option of 390 
expectant management. The predictions for untreated patients were validated using an external 391 
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natural conception cohort of couples with unexplained subfertility from The Netherlands. Whilst this 392 
cohort did not contain follow-up information on those who were treated, we were able to validate 393 
predictions following expectant management. Whilst the criteria for absence of fertility factors in 394 
this validation cohort were not consistent with the criteria used to select cases for the development 395 
cohort, the model still performed well which shows that it is robust and transportable to cohorts 396 
with slightly different diagnostic processes. 397 
Limitations 398 
First, we were unable to adjust for other potentially important predictors that were not available in 399 
the linked Grampian dataset which may have made predictions more specific. These include 400 
ethnicity and measures of ovarian reserve such as Anti-Müllerian hormone or follicle stimulating 401 
hormone (van Loendersloot et al., 2010).  However, we did use the most important predictors of 402 
conception, found in previous research, that are known to the clinician before starting treatment. 403 
These were used in the Hunault model which estimates the chances of natural conception over a 404 
year following diagnosis of unexplained or mild infertility (Hunault et al, 2004). This model is used in 405 
the Netherlands to facilitate decisions around who should receive IVF treatment. Its predictors 406 
include female age, duration of infertility, previous pregnancy status, sperm motility, and referral 407 
status (secondary versus tertiary care). Since we only included couples with unexplained infertility 408 
we had no need to adjust for sperm motility. Also, almost all couples in our cohort were referred 409 
from primary care (93%) so we did not adjust for this variable. It is possible that we may be missing 410 
known and unknown factors that could have confounded the effect of treatment on conception.  411 
Second, since this study was conducted using single centre data, albeit covering a complete region of 412 
Scotland, it may not be generalizable to other centres.  However, this single clinic serves the entirety 413 
of a defined geographical region and the model performed as well as previous models in 414 
reproductive medicine when externally validated using the Dutch cohort (van der Steeg et al., 2007).  415 
The concordance ranged from 0.57 to 0.71 in the development cohort and from 0.56 to 0.68 in the 416 
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validation cohort; previous research has shown that this can be explained by the homogeneous 417 
nature of the population and that calibration is a more important measure of performance (Coppus 418 
et al., 2009).  The fact that we could only source an external cohort with couples under expectant 419 
management for validation reflects the uniqueness of the valuable Grampian dataset. The model 420 
showed only marginal evidence of overfitting with a calibration slope of 0.97 (instead of 1) and there 421 
was slight visible evidence of overprediction in the calibration plot for the first three months.  422 
Third, the modest size of the database and the associated number of treatments commencing in a 423 
given month meant that our model may have lacked precision, especially in the first few months for 424 
treated couples e.g. 16 couples initiated IUI+SO and 15 initiated IVF. The lower numbers for IUI+SO 425 
and IVF are reflected in the wide confidence bands for the predictions in Figure 2 and 3. 18 months 426 
after workup, 399 (53.6%) of the remaining 744 women were still under expectant management so 427 
precisions for that group remained reasonable over follow-up, which is also reflected in the figures.  428 
Our model may have lacked the power to detect whether the relative treatment effect varied by 429 
baseline couple characteristics. Due to modest sample size we attempted to explore whether 430 
baseline prognostic score (a linear combination of individual baseline predictors) varied the chances 431 
of conception following different treatments. This interactive effect was not statistically significant. 432 
Future work will involve prospectively following up a suitable cohort of patients to enable us to fully 433 
validate the model with sufficient statistical power, including refinements and updating of our model 434 
(Steyerberg, 2009).  However, the treatment effect does vary at the absolute risk scale which is most 435 
important for prediction. 436 
Fourth, following the commencement of fertility treatment, during the six month follow-up period 437 
there will be months when couples will not have had further treatment or will have started another 438 
treatment. This means that they could achieve conception either as a result of this treatment, 439 
naturally, or following any other treatment received during follow-up. The same applies to couples 440 
who were under expectant management in a given month but who then received treatment during 441 
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the six month follow-up. However, at the time when the prediction is being made (i.e. at the start of 442 
each month) we do not have this future information available. Our statistical model reflected these 443 
real world pathways observed in the study database. 444 
Fifth, one of the assumptions we make is that couples were trying to conceive naturally during the 445 
‘non-treatment’ periods and after the last treatment received.  For the latter we assume that they 446 
still had an active desire to conceive. 447 
Lastly, since we used historical data, the treatment protocols for similar couples will have changed 448 
over time, favouring IVF post 2008 (HFEA, 2008; HFEA, 2016).  We adjusted for year of registration at 449 
the clinic in the model but it was not a strong predictor of conception. However, the predictions 450 
from the model that we present in Figure 2 and in supplementary text file 3 are based on the most 451 
recent year (i.e. 2012). Therefore predictions will reflect conception chances from couples seen and 452 
treatment received in that year. Further, IVF success rates have not improved since 2012 in the UK - 453 
in 2012 the live birth rate per treatment cycle was 26% whereas in 2016 it was 25% (HFEA, 2018). 454 
Further, other countries still use clomiphene to treat women with unexplained subfertility so these 455 
results will be of interest to clinics around the world. 456 
Comparison with previous fertility prediction models 457 
Previous prediction models only provide a static, i.e., once only, prediction of live birth either at the 458 
point of diagnosis or at the very start of treatment (Leushuis et al., 2009).  The Hunault model 459 
(Hunault et al., 2004), for example, estimates the chance of natural pregnancy leading to live birth 460 
among subfertile couples within one year from their first attendance at a fertility clinic.  It has been 461 
validated and is used in the Netherlands in the form of a web-based calculator to facilitate decisions 462 
around whether a couple should receive fertility treatment straightaway or undergo expectant 463 
management (Kamphuis et al., 2014; Hunault et al., 2005).  However, this model cannot be used to 464 
estimate how a couple’s prognosis changes over time nor to provide predictions following 465 
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commencement of different fertility treatments.  One cannot simply reapply the Hunault model to 466 
the same couple one year later because, by this time, some of the more fertile couples will have 467 
conceived in the intervening time leaving a cohort that is less fertile. Reapplying the model would 468 
result in over predictions which are insufficiently explained by an increase in female age or duration 469 
of subfertility (van Eekelen et al., 2017).  This is evidenced in a recent study that estimated the 470 
chances of natural conception repeatedly over time (van Eekelen et al., 2017).  Conversely, some 471 
prediction models only estimate the chances of live birth following IVF (Templeton et al., 1996; 472 
Nelson and Lawlor, 2011; van Loendersloot et al., 2013; Luke et al., 2014; Dhillon et al., 2015; 473 
McLernon et al., 2016).  Couples also need to know what their chance of natural conception is in 474 
order to determine whether undergoing such invasive and expensive treatment actually improves 475 
their chances.  This problem is acknowledged in the NICE fertility guidelines which attempted to 476 
assess the cost-effectiveness of IVF treatment using the predicted probabilities from two separate 477 
models – one for predicting success following IVF and one for predicting natural conception (Hunault 478 
et al., 2004; National Collaborating Centre for Women’s and Children’s Health, 2013; Nelson and 479 
Lawlor, 2011). 480 
Interpretation and clinical importance 481 
Our analyses show that the predicted chance of success after clomiphene was only slightly higher 482 
than with expectant management, an outcome which is in agreement with results of previous 483 
randomized controlled trials (RCTs) (Hughes et al., 2010).  We found that the chance of conception in 484 
women who started treatment with IUI+SO was higher than for women remaining under expectant 485 
management.  A recent Cochrane review showed that there was no evidence of a difference in live 486 
birth rate between IUI+SO versus expectant management in couples with unexplained subfertility 487 
(Veltman-Verhulst et al., 2016).  However, they acknowledge that the quality of the evidence was 488 
moderate and no subgroup analysis was presented and our result may be explained partially by IVF 489 
cycles occurring following IUI+SO. 490 
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Our results indicate that the chance of live birth following IUI+SO or IVF is higher than that 491 
associated with expectant management. Does this mean that we should treat everyone immediately 492 
(Kamphuis et al., 2014; Kersten et al., 2015)?  Clinicians must consider the absolute chances with and 493 
without treatment on an individual basis together with the cost to the health service (or patient) and 494 
the physical and emotional burden to the woman (Brandes et al., 2011).  A 30 year old woman with 495 
no previous pregnancy who has been trying to conceive for one year has a 31% chance of conceiving 496 
over the next 6 months (and subsequently having a live birth) with expectant management. This 31% 497 
chance also reflects the possibility of starting treatment at some point during that six month follow-498 
up period. If we chose a cut-off of ≥20% to indicate a good prognosis over six months then we would 499 
wait 6 months when her chances drop below that cut-off before deciding to treat. If she started IVF 500 
treatment at month 6 then her chances of conceiving over the subsequent 6 months (which allows 501 
for the fact that further treatments may or may not occur during that time) increase to 67%.  502 
Those couples who start treatment will have subsequent months with and without further 503 
treatment. When making predictions from a month in which such couples do not have treatment, 504 
their chance of conception over the following six months was higher than for couples under 505 
expectant management. This is because these couples are more likely to have (further) treatment 506 
over the following six months than those under expectant management.  507 
The most appropriate use of our model is to facilitate communication between the clinician and the 508 
couple when explaining their chance of conceiving over six months at different points in time when 509 
they are under a period of expectant management and how these chances may improve when they 510 
commence a particular fertility treatment in the future. Couples can then manage their expectations 511 
accordingly. It will also be useful to couples whose first treatment attempt is unsuccessful and who 512 
would like to know what their predicted chances are when continuing treatment. It should be noted 513 
that these predictions are based on historical observational data from couples, not randomised 514 
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controlled trials, and therefore should not be used for decisions regarding treatment effectiveness. 515 
The information should be supported by clinical knowledge. 516 
Further research  517 
Whilst the chance of conception was higher with IVF or IUI+SO compared with expectant 518 
management, the absolute chances varied from couple to couple depending on their characteristics. 519 
Future work should investigate individualised thresholds of predictions to facilitate treatment 520 
decisions. This could mean that having a slightly larger chance of conception with treatment may not 521 
necessarily lead to treatment when balanced with the associated financial, physical and emotional 522 
burden.   523 
We recognise that further validation is necessary in order to strengthen the generalisability and 524 
transportability of the model, particularly in relation to predictions following treatment. In the 525 
absence of such a database we plan to collect a prospective cohort of couples with unexplained 526 
subfertility that will include high quality diagnostic, treatment and outcome information. Following 527 
validation, the model may be converted into an online prediction calculator that can be easily used 528 
in clinical practice to inform couples of their evolving chances of conception.  529 
The predictions from our model will help clinicians to manage the expectations of couples with 530 
unexplained subfertility not only at the diagnostic workup completion but throughout their fertility 531 
journey. 532 
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Figure legends 691 
Figure 1. Dynamic assessment of the model applied to the external validation cohort 692 
A Discrimination using concordance statistic at each month since diagnosis of unexplained 693 
subfertility (95% Confidence Interval (CI)); B calibration plot of observed chance of conception within 694 
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six months (95% CI) versus average predicted probability of conception within six months at each 695 
month since diagnosis of unexplained subfertility. 696 
 697 
Figure 2. Dynamic predictions of conception within six months following expectant management 698 
and treatment. Predictions are made at every month following workup completion (up to 21 699 
months) for:  700 
Couple A who have been trying to conceive for 12 months, with no previous pregnancy, where the 701 
female partner is 30 years old;  702 
Couple B who have been trying to conceive for 24 months, with previous pregnancy, where the 703 
female partner is 40 years old. 704 
Note: The x-axis shows the time in months since the end of diagnostic work-up. At each time point, 705 
the prediction shown is the probability of conception over the following six months given the 706 
treatment status at that time point. The grey vertical reference lines show the predicted probability 707 
of conceiving within six months from six months and twelve months post diagnostic work-up 708 
completion. The left hand plot for Couple A is described in the results section. The right hand plot 709 
(Couple B) shows the dynamic predictions for a couple who have been trying to conceive for two 710 
years, with previous pregnancy, and where the female partner is 40 years old. At the point of their 711 
diagnostic workup completion, the couple have a 12% (95% CI 9% to 16%) chance of conception over 712 
the next 6 months (and subsequently having a live birth) (see expectant management blue line at 713 
month 0). Six months after diagnosis, the couple’s chances of conception over the next six months 714 
reduce to 7% (95% CI 5% to 10%) (see where blue line crossed the dashed vertical reference line). If 715 
the couple start IUI at month six their chance is 20% (95% CI 12% to 28%) (green line) whereas if 716 




Figure 3. Dynamic predictions of conception within six months following expectant management 719 
and treatment for couples with poor, average and good prognosis. Predictions are made at every 720 
month following diagnostic workup completion (up to 21 months) 721 
Poor prognosis couples were taken as the 10th percentile of the prognostic score. The hazard ratios 722 
(95% CI) are: 5.50 (2.69 to 11.23), intrauterine insemination with ovarian stimulation (IUI+SO) versus 723 
expectant management and 5.89 (4.01 to 8.65), IVF versus expectant management. 724 
Average prognosis couples were taken as the 50th percentile of the prognostic score. The hazard 725 
ratios (95% CI) are: 2.87 (2.04 to 4.04), IUI+SO versus expectant management and 5.07 (3.99 to 726 
6.43), IVF versus expectant management. 727 
Good prognosis couples were taken as the 90th percentile of the prognostic score. The hazard ratios 728 
(95% CI) are: 2.00 (1.13 to 3.56), IUI+SO versus expectant management and 4.66 (3.28 to 6.62), IVF 729 
versus expectant management. 730 
 731 
Table I Characteristics of couples with unexplained subfertility at the time of registration at the 




N (%), unless otherwise 
stated 
The Netherlands 
N (%), unless 
otherwise stated 
Total number of women 1316 5235 
Female age, mean (SD) 33.0 (4.9) 32.5 (4.3) 
Female age group, years   
 <31  418 (31.8) 1873 (35.8) 
 31 to 35 485 (36.9) 2239 (42.8) 
 36 to 40 320 (24.3) 941 (18.0) 
 >40 93 (7.1) 182 (3.5) 
No previous pregnancy (female partner) 745 (56.6) 3439 (65.7) 
Duration (mths), median (IQR) 24 (18, 36) 19 (15, 28) 
    
 






Table II Effect of female and couple characteristics and treatment status during follow-up on conception leading to live birth 
Characteristics Hazard ratio (95% CI) p-value 
Female age ≤31 years† 1.01 (0.96 to 1.05) 0.83 
Female age ≥32 years† 0.89 (0.86 to 0.92) <0.001 
Duration of infertility (years) 0.85 (0.79 to 0.92) <0.001 
Previous pregnancy (no v yes) 0.86 (0.71 to 1.03) 0.11 
Year of registration 1.02 (1.00 to 1.05) 0.06 
Treatment status in a month  <0.001 
 Expectant management Ref - 
 Clomiphene 1.42 (1.05 to 1.91) 0.02 
 IUI+SO 2.90 (2.06 to 4.08) <0.001 
 IVF 5.09 (4.04 to 6.40) <0.001 
 Break from treatment 1.50 (1.17 to 1.89) 0.001 
Prediction month+  <0.001 
 S1+ 0.00017 (0.00010 to 0.00028) <0.001 
 S2+ 4.02 (2.45 to 6.61) <0.001 
†Female age had a non-linear relationship with the log hazard of live birth and was modelled as two linear predictors.   
+Prediction month represents the effect of the month when dynamic predictions are made, S1 = (Prediction month/640.5); S2 = (Prediction month/640.5)^2 
Baseline survival at 6 months = 0.61; IUI+SO = ovarian stimulation intrauterine insemination; IVF = in-vitro fertilisation 
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Fertility clinic assessment and tests were performed per protocol, as per the evidence based standard 
operating procedures of the unit based on the NICE guidelines of management of infertility. 
Once a couple was referred by the  GP to the fertility clinic they were seen by a clinician and a detailed history 
and examination was performed in the fertility clinic along with a trans vaginal scan to assess the uterus, the 
ovaries and any adnexal pathology. Patient had a mid-luteal progesterone measurement to confirm ovulation. A 
single semen analysis was required for all men but and was repeated if the first result was abnormal. If the 
patient had an irregular menstrual cycle and features suggestive of PCOS further endocrine investigations such 
as measurement of gonadotropins, prolactin, thyroid and adrenal function, including androgen levels, was done. 
Rubella immunity was established for all women and Chlamydia screening performed if the woman was less 
than 30 years of age. Obese women were referred to the dietician for assessment and weight loss advice. Tests 
for tubal patency were organised in appropriate cases. Laparoscopy and Dye test was the investigation of choice 
for the assessment of pelvic anatomy including tubal patency. HSG was preferred when a less invasive approach 
to assess the pelvis was preferred. The couple then came for a follow-up consultation where the test results were 
discussed and based on the diagnosis further appropriate treatment was organised. 
 
Ovulation induction (Clomiphene/Gonadotropins) 
Women with BMI >30 kg/m2 were given a weight loss target of 5-10% and had a consultation with the nurses 
for Clomiphene chat.  Once the weight loss target was achieved if they were still amenorrhoeic and the 
pregnancy test was negative, Progesterone was given for a withdrawal bleed. Clomiphene 50mg was started 
from day 2-6 of the cycle USS was performed on day 12 of first cycle and day 21 progesterone was checked to 
confirm ovulation. In the absence of ovulation after 2 cycles the dose was increased. In the absence of 
pregnancy after 4 ovulatory cycles a tubal patency assessment was organised and patient was added to IVF 
waiting list. If tubal patency assessment was normal clomiphene was continued for 12 cycles. After 12 ovulatory 
cycles 3 cycles of gonadotropin IUI was offered. If the patient remained anovulatory after 4 cycles of 
clomiphene, gonadotropin IUI was offered for 6 cycles. 
 
Women needing Gonadotrophin induction of ovulation were referred for hour long nurse appointment where the 
procedure was discussed in detail. Gonadotrophin was commenced after a baseline USS and blood test. Low 
dose step up regimen was used. Monitoring was done with serial blood tests and USS. When 1-2 follicles were 
17mm HCG trigger was administered. IUI was performed 30-36 hrs later. 
 
Super ovulation IUI 
Super ovulation IUI was offered to ovulatory women with mild male factor or unexplained infertility. Patient 
had appointment with doctor and nurse for consultation. After normal baseline scan and estradiol levels FSH 
was administered alternate days and monitoring was performed by blood tests and scans from day 8-9.  HCG 
trigger was administered when 1-2 follicles were >17mm and IUI was performed 36 hrs later. 
 
IVF 
A standard long protocol for ovarian stimulation was used for IVF during this period. The initial stimulatory 
dose of follicle-stimulating hormone (FSH) was determined by the age of the patient (150 IU in women less 
than 37years old; 225 IU in 37–39 year olds and 300 IU in women 40 years and above). Women with polycystic 
ovaries were started on 150 IU of FSH. Monitoring during the period of study was performed by ultrasound as 
well as serum estradiol. A human chorionic gonadotrophin (HCG) trigger was administered once at least three 
follicles of more than 17–18 mm diameter were visualized by ultrasound scan. Double-embryo transfer was the 
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Methods: Further details of the statistical analysis 
 
In the dynamic modelling process, the crudest statistical model involved fitting 22 Cox regression analyses, each 
with a separate time origin for each consecutive month with a follow-up window of six months in each. As this 
window slides forward with each successive month any women who conceived (leading to live birth) in the 
previous month(s) were excluded from future models. Rather than fit 22 separate models, we modelled the 
dynamic process in one ‘supermodel’ by adjusting for a function of month.  First of all this involves creating a 
‘super prediction dataset’ using the following steps (van Houwelingen and Putter, 2012): 
 
1. Fix a prediction window, w =six months; 
2. Select a set of prediction time points, called landmarks, in this case every month from 3 to 24 months; 
3. Create a prediction dataset for each landmark by truncation and administrative censoring; 
4. Stack all datasets into a single super prediction dataset. 
 
The variables that change in each of the datasets in point 4 are their respective landmark number, the treatment 
type occurring in that month (clomifene, IUI, IVF treatment gap versus expectant management), and the censoring 
indicator. Known predictors of live birth, such as female age, previous pregnancy history, and duration of 
subfertility were included in the model at their baseline values.  Year of registration was included as a predictor 
to account for changes in practice over the 14 year study period. Other potential predictors such as female smoking 
status and female alcohol status and female BMI were included in the model but removed if they were not 
statistically significant. The chance of conception was known to decline from the female age of 32 years from 
previous studies (Hunault et al, 2004) and this non-linear relationship was confirmed in Martingale residual plots. 
Therefore female age was modelled as a two-piece linear effect. The super Cox model was adjusted for month of 
prediction as a predictor and a robust sandwich estimator was used to adjust the standard errors for the fact that 
one couple contributed information in multiple landmarks, even though only a single conception (leading to live 
birth) was considered as the endpoint. Since female BMI was missing in 20% of women, multiple imputation was 
performed to impute these values. This procedure assumes that missing data were missing at random, conditional 
upon the observed predictors and outcome. BMI was not statistically significant (p=0.99) and was removed from 
the model meaning that the imputed databases were abandoned and only the original dataset used. 
 
Predictive ability  
Discrimination assesses a prediction model’s ability to correctly distinguish between patients who achieve a 
pregnancy (for whom the model assigns a high probability) and do not achieve a pregnancy (for whom the model 
assigns a low probability). We assessed the apparent discriminatory ability of the dynamic prediction model using 
a concordance statistic for survival time data (Kremers 2007).  The concordance statistic allows for tied events in 
time and was calculated for each landmark and its six month follow-up time. Dynamic calibration plots were 
created by plotting the average predicted probability of a pregnancy over six months for each landmark month by 
treatment type and treatment history status.  The plot was then overlaid by the observed probability of pregnancy 
over six months by landmark month calculated using Kaplan-Meier estimator.   
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Initial population  
9975 women with 10548 referrals 
between 1992 and 2011 
Exclusions 
Women under 18 years of age or over 50 
years of age (n=130) 
Women not residing in Grampian 
(Orkney/Shetland n=24; Highlands n=977) 
Women not referred by primary/secondary 
care (n=227) 
Women not referred for infertility problem 
(n=783) 
----At least one of the above (n=1801)---- 
Women who registered at the fertility clinic 
pre-1998 (n=2575) 
Women with lack of treatment records from 
1998 (n=19) 
Women with only donor treatment (n=137) 
---------- 
Data from referrals after the first referral (573 
referrals) 
 
5462 women registered between 
1998 and 2011 
1507 women registered between 
1998 and 2011 with unexplained 
infertility 
 
Exclude women without unexplained 
infertility (n=3955) 
 1316 women included in study 
Exclude women who had live birth 




































5. Prediction of 
conception from 
month 4 (no treatment 
in month 4), P4 
From month 4 the woman has had previous fertility 
treatmentb 
P4 
P9 P8 P7 
Legend 
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 0          1          2           3          4          5           6           7           8            9  ………………….21 
Probability of conception within 6 months from each month following diagnosis of 
unexplained subfertility 
22.  Prediction of 
conception from 
month 21, P21 
Women who conceivea before the start of month 2 no longer contribute 
to the model from that point onwards. This applies to any month. 
4.  Prediction of 
conception from 
month 3 when woman 
starts IVF, P3 
3.  Prediction of 
conception from 
month 2, P2 
6 months 
follow-up 
2.  Prediction of 
conception from 
month 1, P1 
1. Prediction of 
conception within six 
monthsa from completion 
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Note: The top part of the diagram explains the dynamic prediction of conception within six months from diagnostic 
workup and every month thereafter. The conception must have ultimately led to a live birth. The lower part of the 
diagram contains the predicted chances of conception for every possible treatment scenario occurring at every 
month from completion of diagnostic workup. The above example is for a woman who is under expectant 
management until three months post workup completion (the blue dots showing the chances of conception over 
six months from workup completion P0, one month after workup completion P1, and from two months after 
workup completion P2). At month three she starts IVF treatment (the clinician/patient would then read the 
predicted chance of conception from the red dot, P3, at month 3 post workup completion). The woman then has a 
break from treatment for two months (the clinician/patient would then read the predicted chance of conception 
from the green dots, P4 and P5, at months 4 and 5 post workup completion). She then has her second IVF cycle 
at month 6 (the red dot at P6 shows the predicted chance of conception within six months from month 6). 
Assuming she never has further treatment we would then read all predictions from future months at the green 
dots from P7 to P22). 
 
a Conception within six months which leads to a live birth. 














within 2 years 
(%)a 




     
Clomifene 274 (44.4) 265 (47.8) 263 (47.5) 7.1 (4.4 to 11.0) 
IUI+SO 159 (25.8) 152 (27.4) 107 (19.3) 11.1 (7.1 to 14.3) 
Fresh IVF 398 (64.5) 343 (61.9) 184 (33.2) 13.0 (7.8 to 16.4) 
Frozen IVF 94 (15.2) 83 (15.0) 0 (0.0) - 
Any treatment 617 (46.8) 554 (42.1) 554 (42.1) 
10.9 (5.8 to 16.0) 
 
No treatment 699 (53.1) 762 (57.9) 762 (57.9) - 
     
 
IQR=interquartile range  
IUI+SO= intrauterine insemination with ovarian stimulation 
a For individual treatments the denominator is everyone who had a treatment.  For any treatment and no treatment the 
denominator is all women. 
Table S2 Frequency of treatment patterns over the first two years following fertility clinic registration by first treatment 
First treatment Treatment pattern 
No. women 
(%)a 
Clomifene Clomifene Clomifene      30 (11) 
 Clomifene Clomifene Clomifene     30 (11) 
 Clomifene       28 (11) 
 Clomifene Clomifene Clomifene Clomifene Clomifene Clomifene  20 (8) 
 Clomifene Clomifene Clomifene Clomifene Clomifene   16 (6) 
 Clomifene Clomifene Clomifene Clomifene    12 (5) 
 Clomifene Clomifene Clomifene Clomifene Clomifene Clomifene Clomifene 7 (3) 
 Clomifene Clomifene Clomifene Clomifene Clomifene Clomifene Fresh IVF 6 (2) 
 Clomifene Clomifene Clomifene Clomifene Fresh IVF   5 (2) 
 Clomifene Clomifene Clomifene Fresh IVF    5 (2) 
 Others        104 (39) 
IUI+SO IUI+SO       25 (23) 
 IUI+SO IUI+SO      18 (17) 
 IUI+SO IUI+SO IUI+SO     8 (7) 
 IUI+SO IUI+SO Fresh IVF     8 (7) 
 IUI+SO Fresh IVF      7 (7) 
 Others       41 (38) 
IVF Fresh IVF       73 (40) 
 Fresh IVF Fresh IVF      35 (19) 
 Fresh IVF Frozen IVF      14 (8) 
 Fresh IVF Fresh IVF Fresh IVF     11 (6) 
 Fresh IVF Fresh IVF Frozen IVF     5 (3) 
 Others       46 (25) 
Total       554 (100) 
 
IUI+SO= intrauterine insemination with ovarian stimulation  





An example of how to calculate dynamic predictions using the model 
 
To make predictions we calculate the following formula:  S = 1 - Baseline survival^exp(XB) 
where baseline survival is the chance of not conceiving within six months for the reference group (see Table 
below for the relevant value according to the month of prediction) 
Month of prediction Baseline survival 














B = the log hazard ratios from Table 2; and X = the value of the predictors for each couple. 
For example, for Couple A (who have been trying to conceive for 12 months, with no previous pregnancy, 
where the female partner is 30 years old) we want to calculate their chances of conception at baseline, i.e. 
workup completion, over the following six months.  
1. Using the log hazard ratio information (parameter estimates) for each predictor: 
XB = 0.0051*Female age (≤31) - 0.11*Female age (≥32) - 0.16*duration of infertility (years) - 
0.15*previous pregnancy + 0.024*year of registration + (0.35*clomifene + 1.06*IUI+SO + 1.63*IVF + 
0.40*break from treatment) - 8.68*S1 + 1.39*S2 
where 
Female age (≤31) = actual female age in years if age is less than 32; otherwise if female age is greater than 31 
this equals 31; 
Female age (≥32) = if female age is less than 32 this equals zero, if female age greater than 31 this equals age – 
31; 
Duration of infertility = length of time spent trying to conceive prior to first fertility clinic appointment in years; 
Previous pregnancy = 1, if never previously pregnant or =0, if previously pregnant; 
Year of registration always equals zero so ignore; 
2 
 
Treatment (a maximum of only one of the following four treatment groups must equal 1 at any month of 
prediction): 
If having clomifene in month of prediction then set clomifene=1, otherwise 0 
 If having IUI+SO in month of prediction then set IUI+SO =1, otherwise 0 
 If having IVF in month of prediction then set IVF =1, otherwise 0 
 If having break from treatment in month of prediction then set break from treatment =1, otherwise 0 
If under expectant management in month of prediction then set all four of the above to zero; 
S1 = month when dynamic predictions are made in days / 640.5; 
S2 = (month when dynamic predictions are made in days / 640.5)^2. 
 
2. Using the above, XB = 0.0051*30 - 0.11*0 - 0.16*1 - 0.15*1 + 0.024*0 + (0.35*0 + 1.06*0 + 1.63*0 + 
0.40*0) - 8.68*0 + 1.39*0 
XB =  -0.1607 
3. Therefore,  
S = 1 - Baseline survival for month 0^exp(XB) 
S = 1 - 0.6448 ^exp(-0.1607) =  0.31 
i.e. at workup completion couple A have a 31% chance of conception over the following six months. 
 
4. As a further example, if Couple A have IVF treatment six months after workup completion their chances of 
conception over the next six months is: 
XB = 0.0051*30 - 0.11*0 - 0.16*1 - 0.15*1 + 0.024*0 + (0.35*0 + 1.06*0 + 1.63*1+ 0.40*0) - 
8.68*(183/640.5) + 1.39*(183/640.5)^2 
XB = -0.90115 
Therefore,  
S = 1 - Baseline survival for month 6^exp(XB) 
S = 1 - 0.06362 ^exp(-0.90115) =  0.67, i.e. if Couple A have IVF at six months after workup 
completion they have a 67% chance of conception over the following six months. 
